Healthcare / Medical DistributionTaipei Exchange
$67.70
+1.30 (+1.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $88.6M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
9.5x
↓EV/EBITDA
6.4x
↓ROE
16.6%
↑Gross Margin
30.1%
↓Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+33.7%
FCF CAGR
—
FCF margin
-27.7%
FCF / Net income
-1.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.16B · net income $185.5M · FCF $-322.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.16B | $1.16B | $829.0M | $682.2M | $487.3M |
| Net Income | $185.5M | $185.5M | $165.0M | $121.3M | $111.6M |
| EBITDA | $296.2M | $296.2M | $263.7M | $215.7M | $200.7M |
| EPS | — | — | 7.15 | 5.54 | 5.10 |
| Gross Margin | 30.1% | 30.1% | 40.5% | 48.1% | 49.2% |
| Operating Margin | 19.4% | 19.4% | 24.1% | 31.0% | 30.0% |
| Net Margin | 15.9% | 15.9% | 19.9% | 17.8% | 22.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.11 | 0.26 | 0.30 |
| Current Ratio | 3.60 | 3.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-322.1M | $-322.1M | $172.1M | $88.6M | $211.0M |
| Returns | |||||
| ROE | 16.6% | 16.6% | 18.5% | 21.6% | 22.2% |
| Valuation | |||||
| P/E | 9.48 | 9.48 | 13.10 | 16.29 | 8.92 |
| EV/EBITDA | 6.43 | 6.43 | 7.32 | 8.84 | 4.95 |
| P/B | 1.62 | 1.62 | 2.42 | 3.51 | 1.98 |
| Growth & Yield | |||||
| Revenue Growth | 40.5% | 40.5% | 21.5% | 40.0% | — |
| EPS Growth | — | — | 28.9% | 8.7% | — |
| Dividend Yield | 5.5% | 5.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.2%
Start / end P/E
n/dx → n/dx
EPS bridge
7.15 → n/d
Residual
-8.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.